alexa
Reach Us +44-1647-403003
Regulation Of Glioblastoma Stem Cells By Retinoic Acid: Role Of EphB2 Receptor In Glioblastoma Invasion | 5176
ISSN: 2157-7013

Journal of Cell Science & Therapy
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Regulation of glioblastoma stem cells by Retinoic acid: Role of EphB2 receptor in glioblastoma invasion

International Conference & Exhibition on Cell Science & Stem Cell Research

Shuli Xia

ScientificTracks Abstracts: J Cell Sci Ther

DOI: 10.4172/2157-7013.S1.02

Abstract
Human umbilical cord blood-derived msenchymal stem cell (hUCB-MSC) has been regarded as a fascinating candidate of stem cell therapy in neurodegenerative disorders such as alzheimer?s disease (AD). Recently, many groups reported that mesenchymal stem cell is a robust source, not only of regeneration but also of secretion of various soluble factors for damaged or lost host cells. Since we also have been observed paracrine action of hUCB-MSC under a certain pathological condition, we tested whether hUCB-MSC provides therapeutic action against amyloid β (Aβ) neurotoxicity in vitro and in vivo. hUCB-MSC removed Aβ42 signifi cantly through induction of neprilysin expression, Aβ degrading enzyme in microglia cells via paracrine action. We also identifi ed paracrine factors which were secreted from hUCB- MSC to induce neprilysin in microglia. Moreover, the same result was confi rmed in a transgenic mice model of AD. Based on these fi ndings, we received a clearance from Korea Food and Drug Administration (KFDA) and are performing Phase I clinical trial in Korea. In this presentation, I will briefl y introduce our eff orts to develop hUCB-MSC therapeutics for AD from the bench to clinical trial.
Biography
Jong Wook Chang has completed his Ph.D in 2005 from Gwangju-Institute of Science & Technology and postdoctoral studies from Korea-Institute of Science & Technology. He is the NEUROSTEM team leader of Biomedical Research Institute in MEDIPOST Co.,Ltd, a leading group of cord blood MSC therapeutics in South Korea. He also has been worked as a project manager for phase I clinical trial for AD using hUCB-MSC. He has published more than 13 papers after 2008 in reputed journals regarding stem cells and serving as an editorial board member of World Journal of Stem cells
Relevant Topics
Top